These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
880 related articles for article (PubMed ID: 16997182)
1. Thalidomide and lenalidomide in multiple myeloma. Mazumder A; Jagannath S Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182 [TBL] [Abstract][Full Text] [Related]
2. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Morgan G Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634 [TBL] [Abstract][Full Text] [Related]
3. New drugs for myeloma. Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058 [TBL] [Abstract][Full Text] [Related]
4. Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Anderson KC Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in the treatment of multiple myeloma: a review. Armoiry X; Aulagner G; Facon T J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408 [TBL] [Abstract][Full Text] [Related]
6. Thalidomide and lenalidomide in the treatment of multiple myeloma. Kumar S; Rajkumar SV Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Raje N; Hideshima T; Anderson KC Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458 [TBL] [Abstract][Full Text] [Related]
8. Lenalidomide mode of action: linking bench and clinical findings. Davies F; Baz R Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632 [TBL] [Abstract][Full Text] [Related]
9. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. Maier SK; Hammond JM Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850 [TBL] [Abstract][Full Text] [Related]
11. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Anderson KC; Prince HM Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096 [No Abstract] [Full Text] [Related]
13. Lenalidomide: an update on evidence from clinical trials. Dimopoulos MA; Terpos E Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633 [TBL] [Abstract][Full Text] [Related]
14. Treatment paradigms for the newly diagnosed patient with multiple myeloma. Greipp P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097 [TBL] [Abstract][Full Text] [Related]
15. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in multiple myeloma. Thomas SK; Richards TA; Weber DM Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715 [TBL] [Abstract][Full Text] [Related]
20. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Sher T; Miller KC; Lee K; Chanan-Khan A Clin Lymphoma Myeloma; 2009 Aug; 9(4):328-30. PubMed ID: 19717386 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]